Giunta C, Baumann M, Fauth C, Lindert U, Abdalla EM, Brady AF, Collins J, Dastgir J, Donkervoort S, Ghali N, Johnson DS, Kariminejad A, Koch J, Kraenzlin M, Lahiri N, Lozic B, Manzur AY, Morton JEV, Pilch J, Pollitt RC, Schreiber G, Shannon NL, Sobey G, Vandersteen A, van Dijk FS, Witsch-Baumgartner M, Zschocke J, Pope FM, Bönnemann CG, Rohrbach M.
A cohort of 17 patients with kyphoscoliotic Ehlers-Danlos syndrome caused by biallelic mutations in FKBP14: expansion of the clinical and mutational spectrum and description of the natural history.
Gotthardt F., Huber C., Thierfelder C., Grize L., Kraenzlin M., Scheidegger C., Meier C.
Determinants of bone mineral density in men with opioid dependence
J. A. Kanis, C. Cooper, R. Rizzoli5, B. Abrahamsen, N. M. Al-Daghri, M. L. Brandi, J. Cannata-Andia, B. Cortet, H. P. Dimai, S. Ferrar, P. Hadji, N. C. Harvey, M. Kraenzlin, A. Kurth, E. McCloskey, S. Minisola, T. Thomas, J.-Y. Reginster
Identification and management of patients at increased risk of osteoporotic fracture: Outcomes of an ESCEO expert consensus meeting
Kraenzlin M.E., Jakob F.
Schmerzen bei Erkrankungen des Knochens.
Kraenzlin M., Meier C.
Kalziumstoffwechsel.
Meier C., Uebelhart B., Aubry-Rozier B., Birkhäuser M., Bischoff-Ferrari H., Frey D., Kressig R.W., Lamy O., Lippuner K., Stute P., Suhm N., Ferrari S.
Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO/ASCO)
Meier C., Jockers F., Kraenzlin M.
Systemische Mastocytose: Ein 56-jähriger Mann mit einer fortgeschrittenen Osteoporose
Meier C., Kraenzlin M.
Parathormonstoffwechsel.
Seelig E, Meyer S, Timper K, Nigro N, Bally M, Pernicova I, Schuetz P, Muller
B, Korbonits M, Christ-Crain M. Metformin prevents metabolic side effects during systemic glucocorticod treatment.
Struja T, Kaeslin M, Boesiger F, Jutzi R, Imahorn N, Kutz A, Bernasconi L, Mundwiler E, Mueller B, Christ-Crain M, Meienberg F, Ebrahimi F, Henzen C, Fischli S, Kraenzlin M, Meier C, Schuetz P.
External validation of the GREAT score to predict relapse risk in Graves' disease Results from a multicenter, retrospective study with 741 patients.
Struja T., Kutz A., Fischli S., Meier C., Mueller B., Recher M., Schuetz P.
Personalized, immune-modulating treatments for Graves‘ disease: Fact or fiction?
Rueegg C.S., Kriemler S., Zuercher S., Schindera C., Renner A., Hebestreit H., Meier C., Eser P., Vd Weid N.X.
A partially supervised physical activity program for adult and adolsecent survivors of childhood cancer (SURfit): Study design of a randomized controlled trial
Vavanikunnel J., Meier C., Christ E
Primärer (pHPT) und sekundärer Hyperparathyreoidismus (sHPT) - Was ist wichtig für den Hausarzt?